Combining ROR1, CD5 or CD19 targeted chimeric antigen receptors reduces off-tumour toxicity while maintaining lysis against double-positive mantle cell lymphoma cells

Bister A.; Haist C.; Roellecke K.; Ibach T. C.; Hanenberg H.; Gattermann N.; Wiek C.

首页> 外文期刊>Human gene therapy >Combining ROR1, CD5 or CD19 targeted chimeric antigen receptors reduces off-tumour toxicity while maintaining lysis against double-positive mantle cell lymphoma cells

【24h】

Combining ROR1, CD5 or CD19 targeted chimeric antigen receptors reduces off-tumour toxicity while maintaining lysis against double-positive mantle cell lymphoma cells

机译：结合ROR1，CD5或CD19靶向嵌合抗原受体在保持抗肿瘤毒性的同时，同时保持针对双阳性裂缝细胞淋巴瘤细胞的裂解

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Human gene therapy》 |2019年第11期|共2页
作者
Bister A.; Haist C.; Roellecke K.; Ibach T. C.; Hanenberg H.; Gattermann N.; Wiek C.;
展开▼
作者单位

Heinrich Heine Univ Dusseldorf Dusseldorf Germany;

Heinrich Heine Univ Dusseldorf Dusseldorf Germany;

Heinrich Heine Univ Dusseldorf Dusseldorf Germany;

Heinrich Heine Univ Dusseldorf Dusseldorf Germany;

Heinrich Heine Univ Dusseldorf Dusseldorf Germany;

Heinrich Heine Univ Dusseldorf Dusseldorf Germany;

Heinrich Heine Univ Dusseldorf Dusseldorf Germany;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类治疗学;
关键词

相似文献

外文文献
中文文献
专利

1. Combining ROR1, CD5 or CD19 targeted chimeric antigen receptors reduces off-tumour toxicity while maintaining lysis against double-positive mantle cell lymphoma cells [J] . Bister A., Haist C., Roellecke K., Human gene therapy . 2019,第11期

机译：结合ROR1，CD5或CD19靶向嵌合抗原受体在保持抗肿瘤毒性的同时，同时保持针对双阳性裂缝细胞淋巴瘤细胞的裂解
2. Real World Experience of Tisagenlecleucel Chimeric Antigen Receptor (CAR) T-Cells Targeting CD19 in Patients with Acute Lymphoblastic Leukemia (ALL) and Diffuse Large B-Cell Lymphoma (DLBCL) Using the Center for International Blood and Marrow Transplant Research (CIBMTR) Cellular Therapy (CT) Registry [J] . Pasquini Marcelo, Hu Zhen-Huan, Zhang Yiyun, Clinical lymphoma, myeloma & leukemia . 2019,第Suppla1期

机译：Tisagenlecleulel嵌合抗原受体（汽车）T细胞的真实世界经验靶向CD19患者急性淋巴细胞白血病（ALL）和弥漫性大B细胞淋巴瘤（DLBCL）使用国际血液和骨髓移植研究（CIBMTR）细胞治疗（CT）注册处
3. Phase II trial of co‐administration of CD19‐ and CD20‐targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma [J] . Wei Sang, Ming Shi, Jingjing Yang, Cancer Medicine . 2020,第16期

机译：CD19-和CD20靶向嵌合抗原受体T细胞共施加的CD19-和CD20靶向嵌合抗原受体T细胞的II期试验进行复发和难治性弥漫性大B细胞淋巴瘤
4. MAINTAINING CD4/CD8 RATIO AND TH1-CTL SUBSETS OF CHIMERIC ANTIGEN RECEPTOR (CAR)-T CELLS IN SERUM-FREE CULTURE CONDITIONS [C] . Hsin-Lin Lu, Pei-Ju Leng, Yu-Hua Su, Conference on advancing manufacture of cell and gene therapies . 2019

机译：在无血清培养条件下维持嵌合抗原受体（CAR）-T细胞的CD4 / CD8比率和TH1-CTL亚群
5. Integration Mapping of piggyBac-Mediated CD19 Chimeric Antigen Receptor T Cells Analyzed by Novel Tagmentation-Assisted PCR [D] . Hamada Motoharu, 濱田太立 2019

机译：通过新型标记辅助PCR分析piggyBac介导的CD19嵌合抗原受体T细胞的整合图谱
6. Phase II trial of co‐administration of CD19‐ and CD20‐targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma [O] . Wei Sang, Ming Shi, Jingjing Yang, 2020

机译：CD19-和CD20靶向嵌合抗原受体T细胞共施加的CD19-和CD20靶向嵌合抗原受体T细胞的II期试验进行复发和难治性弥漫性大B细胞淋巴瘤
7. Cutting Edge: ROR1/CD19 Receptor Complex Promotes Growth of Mantle Cell Lymphoma Cells Independently of the B Cell Receptor–BTK Signaling Pathway [O] . Qian Zhang, Hong Y. Wang, Xiaobin Liu, 2019

机译：切削刃：ROR1 / CD19受体复合物促进披露细胞淋巴瘤细胞的生长，与B细胞受体-BTK信号通路无关

Combining ROR1, CD5 or CD19 targeted chimeric antigen receptors reduces off-tumour toxicity while maintaining lysis against double-positive mantle cell lymphoma cells

著录项

相似文献

相关主题

期刊订阅